Blue­bird whis­tles up a co-de­vel­op­ment/co-pro­mo­tion pact with Cel­gene on bb2121 CAR-T

Blue­bird bio $BLUE has picked up an op­tion to co-pro­mote and co-de­vel­op its close­ly-watched an­ti-BC­MA CAR-T bb2121 for mul­ti­ple myelo­ma pa­tients along­side Cel­gene $CELG.

Hav­ing worked to­geth­er over the past 5 years, blue­bird says it will cov­er half of the de­vel­op­ment costs for bb2121, be­gin­ning in April, while look­ing to split the prof­its it gen­er­ates in the US. Cel­gene is in con­trol out­side the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER